{"id":"W4200095907","doi":"10.1200/jco.21.00941","title":"Health-Related Quality of Life in Metastatic, Hormone-Sensitive Prostate Cancer: ENZAMET (ANZUP 1304), an International, Randomized Phase III Trial Led by ANZUP","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":60,"is_retracted":false,"has_abstract":true,"ca_institutions":"Kingston Health Sciences Centre; University of Ottawa; Alberta Cancer Foundation; BC Cancer Agency","funders":"National Health and Medical Research Council; Australian and New Zealand Urogenital and Prostate Cancer Trials Group; Astellas Pharma","keywords":"Medicine; Enzalutamide; Quality of life (healthcare); Prostate cancer; Internal medicine; Discontinuation; Randomized controlled trial; Cancer; Oncology; Physical therapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.01616674,0.0002000214,0.005234876,0.0002331051,0.00004143418,0.00001568025,0.0001735421,0.0002551402,0.0002566417],"category_scores_gemma":[0.01397563,0.0001366695,0.0007684714,0.0003321748,0.0005133611,0.0002525978,0.00006492323,0.001246521,0.00000296181],"about_ca_system_candidate":true,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0004592308,"about_ca_system_score_gemma":0.009163462,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001223045,"about_ca_topic_score_gemma":0.0003561678,"domain_scores_codex":[0.986506,0.005592915,0.006439609,0.0003374222,0.0007697545,0.0003542386],"domain_scores_gemma":[0.9880628,0.005384602,0.004226775,0.0002320621,0.001406556,0.0006872131],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9436463,0.008879023,0.001511503,0.00004493329,0.002666625,0.0007803845,0.001031719,0.00001324253,0.001114298,0.00007871783,0.003613949,0.03661933],"study_design_scores_gemma":[0.9765884,0.01422427,0.003044818,0.0001389725,0.0003866741,0.00005748349,0.0007515281,0.0003067752,0.0005470663,0.0003322145,0.003503506,0.0001182509],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.954419,0.007128731,0.00006998602,0.03522462,0.001393054,0.001265061,0.000123706,0.000008184711,0.0003676208],"genre_scores_gemma":[0.9671723,0.0284964,0.001152284,0.001732378,0.0004389398,0.0000439469,0.0001331218,0.00002214206,0.0008084425],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.03650108,"threshold_uncertainty_score":0.9964536,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.2063521967947266,"score_gpt":0.5675658819912144,"score_spread":0.3612136851964878,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}